<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Alprostadil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00770</strong>&#160; (APRD00785)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00770/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00770/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00770.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00770.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00770.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00770.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00770.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00770">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Alprostadil</td><td>German</td><td>INN</td></tr><tr><td>Alprostadil</td><td>French</td><td>INN</td></tr><tr><td>Alprostadil</td><td>Spanish</td><td>INN</td></tr><tr><td>Alprostadil Alfadex</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>BAN</td></tr><tr><td>Alprostadilum</td><td>Latin</td><td>INN</td></tr><tr><td>PGE&#8321; </td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>PGE1 &#945;-CD</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alista</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Alprostadil</td><td>Bedford</td></tr><tr><td>Alprostan</td><td>Zentiva</td></tr><tr><td>Alprostapint</td><td>Closter</td></tr><tr><td>Alprostar</td><td>Recordati</td></tr><tr><td>Alprostin</td><td>Pfizer</td></tr><tr><td>Alprox-TD</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Altesil</td><td>Taiyo Pharmaceutical</td></tr><tr><td>Alyprost</td><td>Fuji Yakuhin</td></tr><tr><td>Apistandin</td><td>Fuji Yakuhin</td></tr><tr><td>Aplicav</td><td>Libbs</td></tr><tr><td>Befar</td><td>Nexmed</td></tr><tr><td>Bolesi</td><td>Yaoyou Pharmaceutical</td></tr><tr><td>Bondil</td><td>Meda</td></tr><tr><td>Cardiobron</td><td>Fada</td></tr><tr><td>Caverject</td><td>Pfizer</td></tr><tr><td>Caverject DC</td><td>Pfizer</td></tr><tr><td>Caverject Dual</td><td>Pfizer</td></tr><tr><td>Edex</td><td>Schwarz</td></tr><tr><td>Eglandin</td><td>Welfide</td></tr><tr><td>Femprox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Kai Tong</td><td>Jilin Yuhua Pharmaceutical Co.</td></tr><tr><td>Kaishi</td><td>Tide Pharmaceutical</td></tr><tr><td>Karon</td><td>Zentiva</td></tr><tr><td>Liple</td><td>Tanabe Mitsubishi Pharma</td></tr><tr><td>Minprog</td><td>Pfizer</td></tr><tr><td>Muse</td><td>AstraZeneca</td></tr><tr><td>Palux</td><td>Taisho Yakuhin</td></tr><tr><td>Pridax</td><td>Gebro</td></tr><tr><td>Prink</td><td>Taiyo Pharmaceutical</td></tr><tr><td>Prolisina VR</td><td>Pfizer</td></tr><tr><td>Prostandin</td><td>Ono Yakuhin</td></tr><tr><td>Prostavasin</td><td>Schwarz</td></tr><tr><td>Prostin VR</td><td>Pfizer</td></tr><tr><td>Prostin VR Pediatric</td><td>Pfizer</td></tr><tr><td>Prostivas</td><td>Pfizer</td></tr><tr><td>Sugiran</td><td>Esteve</td></tr><tr><td>Tandetron</td><td>Takata Seiyaku</td></tr><tr><td>Topiglan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vasaprostan</td><td>Bayer</td></tr><tr><td>Vasoprost</td><td>UCB</td></tr><tr><td>Vasostenoon</td><td>Kevelt</td></tr><tr><td>Viridal</td><td>UCB</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Caverject Sterile Powder - Kit 11.9mcg /Vial</td><td>Alprostadil + Water</td></tr><tr><td>Caverject Sterile Powder - Kit 23.2mcg/Vial</td><td>Alprostadil + Water</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>745-65-3</td></tr><tr><th>Weight</th><td>Average: 354.481<br>Monoisotopic: 354.240624198</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>34</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>GMVPRGQOIOIIMI-DWKJAMRDSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Eicosanoids</td></tr><tr><th>Subclass</th><td>Prostaglandins and related compounds</td></tr><tr><th>Direct parent</th><td>Prostaglandins and related compounds</td></tr><tr><th>Alternative parents</th><td>Keto Fatty Acids; Carbocyclic Fatty Acids; Fatty Alcohols; Unsaturated Fatty Acids; Secondary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>fatty alcohol; cyclic alcohol; secondary alcohol; ketone; polyamine; carboxylic acid derivative; enolate; carboxylic acid; alcohol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.</td></tr><tr><th>Pharmacodynamics</th><td>Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora.&#160;As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops.&#160;This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.</td></tr><tr><th>Mechanism of action</th><td>Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability of alprostadil has not been determined.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Bound in plasma primarily to albumin (81% bound) and to a lesser extent alpha-globulin IV-4 fraction (55% bound).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by beta- and omega-oxidation.</p></td></tr><tr><th>Route of elimination</th><td>Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by &#946;- and &#969;-oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration.</td></tr><tr><th>Half life</th><td>5 to 10 minutes (after a single dose), in healthy adults and neonates.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 186 mg/kg; Oral, rat: LD<sub>50</sub> = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9815</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8704</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5245</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5554</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9202</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8983</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9064</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8211</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8834</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5292</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9502</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9725</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9387
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9201
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6056
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9631 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9087
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9138
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bedford laboratories div ben venue laboratories inc</li>
<li>Teva parenteral medicines inc</li>
<li>Pfizer inc</li>
<li>Pharmacia and upjohn co</li>
<li>Schwarz pharma ag</li>
<li>Vivus inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Nutrimol De Mexico Sa De Cv</li>
<li><a href="http://www.paladin-labs.com">Paladin Laboratories Usa Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Schwarz Pharma Inc.</li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.vetter-pharma.com">Vetter Pharma Fertigung GmbH and Co. KG</a></li>
<li><a href="http://www.vivus.com">Vivus</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Intra-arterial</td><td></td></tr><tr><td>Suppository</td><td>Urethral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1709">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6325">MS/MS Spectrum LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1650">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>